488
Views
6
CrossRef citations to date
0
Altmetric
Research Article

A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas

, , , , , , , & show all
Pages 1288-1294 | Received 23 Jun 2013, Accepted 25 Aug 2013, Published online: 01 Nov 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Andrea Janikova, Zbynek Bortlicek, Vit Campr, Natasa Kopalova, Katerina Benesova, Jitka Hamouzova, David Belada, Vit Prochazka, Robert Pytlik, Samuel Vokurka, Jan Pirnos, Juraj Duras, Heidi Mocikova, Jiri Mayer & Marek Trneny. (2016) Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. Leukemia & Lymphoma 57:5, pages 1094-1103.
Read now

Articles from other publishers (5)

Sonali Smith. (2021) Too much and not enough: revisiting maintenance rituximab in indolent lymphomas. Haematologica 107:2, pages 353-354.
Crossref
Marcela Osovská, Andrea Janíková, Leoš Křen & Andrea Marečková. (2019) Chronic Benign CD8+ Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse. Case Reports in Hematology 2019, pages 1-4.
Crossref
C.Y. Cheah, D. Chihara, M. Ahmed, R.E. Davis, L.J. Nastoupil, K. Phansalkar, F.B. Hagemeister, L.E. Fayad, J.R. Westin, Y. Oki, M.A. Fanale, J.E. Romaguera, M.L. Wang, H. Lee, F. Turturro, F. Samaniego, M.A. Rodriguez, S.S. Neelapu & N.H. Fowler. (2016) Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology 27:5, pages 895-901.
Crossref
Christian TavernaGiovanni MartinelliFelicitas HitzWalter MingroneThomas PabstLidija CevreskaAuro del GiglioAnna VanazziDaniele LaszloJohann RaatsDaniel RauchDaniel A. VorobiofAndreas LohriChristine Biaggi RudolfStéphanie RondeauCorinne RusterholzIngmar A.F.M. HeijnenEmanuele ZuccaMichele Ghielmini. (2016) Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. Journal of Clinical Oncology 34:5, pages 495-500.
Crossref
Jonathan W. Friedberg. (2014) End of Rituximab Maintenance for Low–Tumor Burden Follicular Lymphoma. Journal of Clinical Oncology 32:28, pages 3093-3095.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.